Navigation Links
Self-directed behavioral IBS treatment rapidly relieves even the most severe symptoms
Date:5/12/2010

BUFFALO, N.Y. -- Nearly one-third of patients with irritable bowel syndrome (IBS) who underwent a novel behavior treatment developed by a University at Buffalo behavioral scientist achieved significant relief within four weeks of beginning treatment.

These patients, called "rapid responders" maintained their improvement at a three-month follow-up, despite reporting more severe IBS symptoms when they started the treatment.

Results also showed that the amount of "face time" spent with a therapist during the 10-week treatment regimen didn't have an effect on rapid response.

The study is published in the current issue of the journal Clinical Gastroenterology and Hepatology.

"These results are important, because conventional wisdom states that benefit from behavioral treatments is tied to the amount of treatment patients receive," says first author Jeffrey Lackner, PsyD, associate professor in the Department of Medicine, UB School of Medicine and Biomedical Sciences, and director of its Behavioral Medicine Clinic.

"In some patients this assumption does not prove to be true," he continues. "Regardless of whether patients received two or four sessions of behavioral treatment, a significant proportion rapidly achieved significant relief of severe IBS symptoms and maintained these gains for at least three months."

Irritable bowel syndrome is a chronic, debilitating disorder affecting 25 million people in the U.S. -- 14-24 percent of women and 5-19 percent of men. In the past, there had been no reliable, satisfactory medical treatment for the full range of IBS symptoms, which can cause severe physical and psychological distress and deprive sufferers of their quality of life.

Lackner is principal investigator on an $8.9 million, seven-year, multi-site clinical trial funded by the National Institute of Diabetes, Digestive and Kidney Diseases (NIDDK) to test the treatment, which proved effective during his pilot study. The UB trial is the largest IBS clinical trial conducted to date, and one of the largest behavioral trials without a drug component funded by the NIH.

The current study involved 71 participants from its UB site who were randomized to receive either four one-hour sessions with a behavioral therapist over 10 weeks, 10 one-hour sessions over 10 weeks or to a "wait" group, which served as a control.

Researchers were interested in knowing if patients who showed significant improvement soon after beginning treatment maintained that improvement at three months after the 10-week intervention, and if so, how these rapid responders were different from the non-rapid responders.

Lackner says they found a strong connection between participants' beliefs about their IBS symptoms and their rapid response and maintenance of improvement.

"Rapid responders were more likely to attribute their symptoms to their own specific behavior, express more confidence in their ability to make specific behavior changes necessary to control IBS symptoms and have stronger motivation to participate in a self-management program," says Lackner.

"One might assume that the therapist-directed, time-intensive and highly structured weekly cognitive behavior therapy would be more likely to promote a more rapid response. That turned out not to be the case."

In addition, 92.5 percent of rapid responders showed an enduring benefit that lasted well over three months with little evidence of deterioration.

"This suggests that rapid response is a relatively robust, clinically meaningful and enduring clinical phenomenon," says Lackner. "The enduring nature of the response to treatment argues against the idea that the results are due to placebo."

He continues: "The study has implications for designing clinical trials that test the effectiveness of medical therapies. Generally speaking, the approach has been to test two treatments side by side. This horse race approach is useful, but may not provide information about the more pressing question of: which treatment works best for which patient?

"Our study suggests that what goes on during treatment may be more important to understanding the course of outcome than factors such as the severity of their illness, age, gender and education level. Generally speaking, these variables are not reliable predictors of outcome."


'/>"/>

Contact: Lois Baker
ljbaker@buffalo.edu
716-645-4606
University at Buffalo
Source:Eurekalert

Related medicine news :

1. Brandeis University undertakes third national survey of health plans behavioral health services
2. Three New Behavioral Health Companies Sign On With MyOutcomes
3. Self-Psychology Allows You to Carry A Cognitive Behavioral Therapist On Your iPhone
4. Behavioral Laboratory Cracks the DNA Code of Happiness
5. Synergy between behavioral and pharmacologic interventions for ADHD
6. Centenes Arizona Behavioral Health Unit Awarded Expanded Contract
7. Haven Behavioral War Heroes Hospital to Offer Comprehensive Psychiatric Treatment for Military Service Members
8. Qualifacts is Behavioral Health SaaS Provider of Choice in Connecticut
9. Novel program translates behavioral and social science research into treatments to reduce obesity
10. Chronic Back Pain Soothed by Cognitive Behavioral Therapy
11. State of Oregon Department of Human Services Selects Netsmart Technologies for Comprehensive Behavioral Healthcare Integration Project
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... Middletown, PA (PRWEB) , ... May 31, 2016 , ... ... in the United States, and more than 100,000 physical therapy clinics. Each physical ... for the benefit of clients. At the same time, staying afloat in a competitive ...
(Date:5/31/2016)... ... May 31, 2016 , ... Fire Door ... has joined the Fire Door Solutions’ team. Keith will serve Fire Door ... frame in-field re-labeling. He will be instrumental in developing educational curriculum and ...
(Date:5/31/2016)... ... May 31, 2016 , ... More than 80 representatives of ... Philadelphia, and the Prevent Cancer Foundation held an event on National Hepatitis Testing Day ... city of viral hepatitis, the leading cause of liver cancer. , Foundation leaders and ...
(Date:5/31/2016)... ... May 31, 2016 , ... St. Joseph ... regional health information exchange, which enables physicians at SJMC’s two hospital campuses, downtown ... other participating organizations in the exchange. SJMC’s membership in the health information exchange ...
(Date:5/31/2016)... ... May 31, 2016 , ... When MetLoop first demonstrated its ... something that contractors should have at their disposal on a daily basis. , ... Director of Contractor Programs. , As a result, Metloop and CertainTeed entered ...
Breaking Medicine News(10 mins):
(Date:5/31/2016)... Switzerland , May 31, 2016 ... announced the initiation of a first-in-human clinical trial of ... fusion molecule - S101 is currently being developed for ... 1 study is designed to evaluate the safety and ... conducted at several sites across the United ...
(Date:5/31/2016)... The global biomaterials market is driven by the ... from chronic diseases. According to research report, "Global Biomaterials Market ... Forecasts (2016-2021) - (By Value; By Material Type - Polymer, ... By Region-North America, Europe , APAC, ROW; ... Italy , Japan , ...
(Date:5/31/2016)... , May 31, 2016 ... World Health Assembly zur Eliminierung von viraler Hepatitis ... Mitgliedsstaaten eine historische Verpflichtung eingegangen, virale Hepatitis bis ... . World Health Assembly haben sich die ... bzgl. viraler Hepatitis (Global Viral Hepatitis Strategy) zu ...
Breaking Medicine Technology: